/ Print /

Pharmacy Best Practices

Four ways healthcare executives can gain consumer trustInsurers are gaining trust while pharma moves backwards in trust. Find out why.
Effective patient messaging drives higher value healthcareMedication non-adherence is a growing issue for patients, physicians and health plans. Here’s one effective solution.
Biosimilars uptake may lag for cancer patients, physiciansBiosimilars will have a significant impact on cancer treatment, with the potential to drive cost savings, but will patients and providers be accepting?
Experts debate best treatment for metastatic colorectal cancer patientsDe-escalated maintenance or “drug holidays”: What’s best for patients with metastatic colorectal cancer?
Weighing value in HER2+ breast cancer treatmentTargeted treatments of HER2-positive breast cancers have dramatically prolonged many patients’ lives. But treatment outcomes in clinical trial settings don’t always translate into comparable real-world clinical value.
Patients demand access to investigational therapiesExpanded access or “compassionate use” programs allow patients to use investigational treatments, medical devices, or tests, before they have received FDA approval.
How biomarkers can personalize cancer immunotherapyASCO 2016 presenters share how combination therapies and biomarkers can better identify which tumors are likely to succumb to particular immunotherapies
‘Game changing’ migraine drugs on the horizonThere’s no silver bullet for migraine treatments, but treatments are getting more precise as we learn more about the cause of migraines.
Four critical components for successful, value-based pharma contractsDespite their proliferation, at-risk pharma contracts are still little more than value-based window dressing. Here are four critical components of contracts that can actually move the value meter in the right direction.
New agreement supports value-based pharma contractingIndustry experts are using their proprietary data/analysis to help structure contracts between pharmaceutical companies and plans.